Atila PGx Oncology & Immunosuppression SNP Panel
Genotyping of 41 pharmacogenomic SNPs across 6 genes predicting chemotherapy toxicity and drug disposition.
Each kit includes 100 tests. This product is for Research Use Only (RUO).
Atila PGx Oncology & Immunosuppression SNP Panel
Several oncology PGx markers carry the strongest evidence in the field. DPYD variants predict severe, potentially fatal fluoropyrimidine (5-FU/capecitabine) toxicity; TPMT and NUDT15 predict thiopurine-induced myelosuppression (also used in IBD/autoimmune care); and CYP2D6 governs tamoxifen→endoxifen activation in ER+ breast cancer. ABCB1 and CYP2C8 add chemo-disposition context.
Features Include
Technical Specs
Workflow Overview for the Atila PGx Oncology & Immunosuppression SNP Panel
This section is for demonstrative purposes only and may be incomplete or inaccurate. Always refer to the product instructions for precise guidelines and directions.
Prepare the sample–master mix
For each sample, combine 2 µL of PCR master mix with 1 µL of genomic DNA to make a 3 µL-per-reaction mix. Scale the volume to the number of assay wells required for that sample.
Load the panel plate
Dispense the combined master mix–sample mixture into each assay well of the pre-arrayed panel plate. Seal the plate and briefly centrifuge to collect the reaction at the bottom of each well.
Run real-time PCR
Load the plate onto a Bio-Rad CFX or Applied Biosystems Quant Studio real-time PCR system and run the standard PCR cycling protocol.
Data analysis
Import the run file into the accompanying analysis software for automated allele calling and genotype determination across all panel SNPs.
Obtain result report
The software generates a structured pharmacogenetics report translating each genotype into gene-level phenotype and drug-response context.